Compare FedEx Corporation (FDX) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

FedEx (FDX) trades at $291.73, up 0.93% with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 15.73 and net income margin of 4.68%, though revenue has declined from $93.5B in 2022 to $87.9B in 2025. Recent developments include a $300 million electric truck order and strong shareholder support for management.

Wall Street remains bullish with a $307.55 consensus target (57% buy ratings), but rising fuel costs and competitive pressures pose risks. The stock offers value pricing with P/S of 0.74 and positive cash flow projection for 2026, though technical indicators suggest near-term resistance around $294-299.

INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.

Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.